COVID-19
Today, activists with the AIDS Healthcare Foundation are setting up to protest in front of Moderna’s Cambridge headquarters.
The trial will enroll about 4,000 people worldwide to confirm the drug’s safety and immunogenicity profiles.
A new study on COVID-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection.
A new variant, C.1.2. is causing public health experts worldwide to keep an eye out for its presence as it seems to be more infectious and even more resistant to vaccines than other variants.
At the six-month mark, 68% of participants reported at least one persistent symptom, which fell to 49% after one year.
Scientists from the U.K. conducted a massive study on the link between vaccinations and dropping platelet counts and found that the problem lies more on the virus itself than on the medications.
As many children go back to school, new waves of COVID-19 cases continue to surge. More data keeps coming in on potential vaccine risks and how they measure up against the risk of the disease. Here’s a look.
The CDC is taking a proactive stance and establishing a center that will use forecasting and outbreak analytics to guide public health decision-making.
Early data from a Phase III study for COVID-19 shows significant promise with its combo therapy reduced death and hospitalization in trial patients at high risk of progression by 78%.
The development of COVID-19 vaccines, which took only months from the initial gene sequencing to the time shots were in arms, was the biggest story of 2020 alongside the pandemic itself.
PRESS RELEASES